Monday, September 22, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Tilray Files Prospectus Supplement for Resale of 124 Million Shares of Common Stock

Elaine Mendonca by Elaine Mendonca
January 10, 2024
in Breaking News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Tilray, a leading player in the pharmaceutical and cannabis industry, has recently taken a significant step towards expanding its market presence. In a move that highlights its commitment to transparency and compliance, the company has filed a prospectus supplement on January 10, 2024. This filing aims to register the resale of an impressive 12.4 million shares of common stock by a selling stockholder.

The prospectus supplement, which can be accessed on the U.S. Securities and Exchange Commission (SEC) website, offers a comprehensive overview of the offering, shedding light on the company’s financial condition and other pertinent details. It serves as a valuable resource for investors and stakeholders seeking a deeper understanding of Tilray’s current position and future prospects.

To access the complete filing and delve into the intricate details of this exciting development, interested parties are encouraged to visit the SEC website. This filing underscores Tilray’s dedication to maintaining transparency and providing its stakeholders with the necessary information to make informed decisions.

[bs_slider_forecast ticker=”TLRY”]

Analyzing Tilray Inc.s Stock Price Drop on January 10, 2024: Factors and Implications

On January 10, 2024, Tilray Inc. (TLRY) experienced a significant drop in its stock price. The stock closed at $2.11, marking a decrease of $0.23 since the previous market close, translating to a decline of 9.83% in TLRY shares. TLRY was trading in the middle of its 52-week range, suggesting that its price was neither at its highest nor lowest point within the past year. Additionally, the stock was below its 200-day simple moving average, indicating a potential bearish trend. The drop in TLRY’s stock price on January 10, 2024, may have been influenced by various factors, and investors and analysts would likely examine these factors to gain a better understanding of the reasons behind the drop and to assess the potential implications for the company’s future performance. It is important to note that stock prices can be volatile, and daily fluctuations are a common occurrence. Therefore, a single day’s performance should not be taken as a definitive indicator of a company’s overall financial health or long-term prospects. Investors are advised to consider a range of factors, including historical performance, industry trends, and company fundamentals, when making investment decisions.

[stock_market_widget type=”chart” template=”basic” color=”#3946CE” assets=”TLRY” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” api=”yf”]

TLRY Stock Performance: Total Revenue and Net Income Analysis on January 10, 2024

TLRY Stock Performance on January 10, 2024:

– Total revenue for Tilray Inc. (TLRY) in the past year was $627.12 million.
– Total revenue in the previous quarter was $193.77 million, showing a flat performance since last year.
– There was a 9.51% increase in total revenue since the previous quarter.
– Net income for the past year was -$1.45 billion, indicating a significant loss.
– Net income in the second quarter improved to -$49.01 million, showing a 31.48% increase since the previous quarter.
– Net income decreased by 204.67% since the previous year.
– Earnings per share (EPS) for the past year was -$2.35, indicating a loss per share.
– EPS in the second quarter improved to -$0.07, showing a 35.17% increase since the previous quarter.
– EPS decreased by 137.24% since the previous year.
– Tilray’s financial performance has been mixed, with positive growth in total revenue and net income since the previous quarter, but significant challenges indicated by the decrease in net income and EPS since the previous year.
– The cannabis industry, in which Tilray operates, has faced regulatory hurdles and market volatility in recent years, which can impact financial performance.
– Investors and analysts will closely monitor Tilray’s future financial reports to assess its ability to overcome challenges and achieve sustainable growth.
– Thorough research and consideration of various factors, including industry trends, competitive landscape, and management strategies, are important when evaluating stock performance and making investment decisions.

Tags: TLRY
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

AZZ Inc Reports Impressive ThirdQuarter Results

COST stock news

MKS Instruments A Promising Outlook for 2024

COST stock news

Analyst Reiterates Positive Stance on SMART Global Holdings with Increased Price Target

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recommended

Data-security

Expansion of SOBR Safe Inc in Canada through Strategic Partnership with TrTek Monitoring Services

2 years ago
COST stock news

Analysts Provide Mixed Views on Marvell Technology Incs Performance

2 years ago
Cummins Stock

A Tale of Two Technologies: Cummins Navigates AI Boom and Green Transition

3 weeks ago
Film

Bearish Sentiment Prevails in Charter Communications Options Market

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe Alibaba Alphabet Amazon AMD AMZN Apple ASML BA BigBear.ai BioNTech Broadcom Coinbase Eli Lilly Fiserv Hims & Hers IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Opendoor Oracle Oxford Lane Capital Palantir PayPal Pepsi Red Cat Robinhood Rocket Lab USA Salesforce Strategy Tesla TSLA Unitedhealth Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

A Dual-Thrust Investment: The iShares U.S. Aerospace & Defense ETF

Lixiang Education Shares Surge Amid Conflicting Market Signals

OFS Credit Faces Market Pressure Following Quarterly Earnings Miss

Navigating Market Volatility with the Invesco S&P 500 Quality ETF

Microsoft Navigates AI Expansion Amid Immigration Policy Shift

Salesforce Leadership’s Stock Sales Raise Investor Concerns

Trending

KalVista Stock
Analysis

KalVista’s Regulatory Victory Meets Market Skepticism

by Felix Baarz
September 22, 2025
0

While KalVista Pharmaceuticals achieved a significant regulatory milestone with European and Swiss approval for its hereditary angioedema...

ASML Stock

ASML Faces Mounting Headwinds as Analyst Sentiment Sours

September 22, 2025
MSCI World ETF Stock

Global Equity ETF Heavily Reliant on US Tech Titans

September 22, 2025
iShares U.S. Aerospace & Defense ETF Stock

A Dual-Thrust Investment: The iShares U.S. Aerospace & Defense ETF

September 22, 2025
Lixiang Education Holding Stock

Lixiang Education Shares Surge Amid Conflicting Market Signals

September 22, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • KalVista’s Regulatory Victory Meets Market Skepticism
  • ASML Faces Mounting Headwinds as Analyst Sentiment Sours
  • Global Equity ETF Heavily Reliant on US Tech Titans

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com